Valeria Visco1, Cristina Esposito2, Paolo Vitillo1, Carmine Vecchione1,3, Michele Ciccarelli1. 1. Department of Medicine, Surgery and Dentistry, University of Salerno, Via Salvador Allende, 84081 Salerno, Italy. 2. Cardiology Unit, University Hospital "San Giovanni di Dio e Ruggi d'Aragona", Largo Città di Ippocrate, 84131 Salerno, Italy. 3. Vascular Physiopathology Unit, IRCCS Neuromed, Via Atinense 18, 86077 Pozzilli, Isernia, Italy.
Abstract
BACKGROUND: In the past years, different devices have been investigated to help in identifying early decompensation events in patients with heart failure (HF) and reduced ejection fraction (EF), reducing hospital admissions. In this report, we present the first patient experience with levosimendan infusion led by CardioMEMS. CASE SUMMARY: A 68-year-old man with HF and reduced EF with more than 20 hospitalizations for exacerbation of HF was enrolled in our HF Clinic from October 2017. Echocardiogram showed a dilated left ventricle with severely reduced EF (29%) and increased pulmonary artery systolic pressure (40 mmHg). From October 2017 to May 2019, the patient went through numerous hospitalizations, despite optimal medical therapy; subsequently, was adopted a strategy of levosimendan infusions guided by CardioMEMS. Levosimendan infusions improved haemodynamic and pressure profiles. The patient was monitored daily by CardioMEMS, and from June to December 2019, he had only two hospitalizations scheduled for levosimendan infusion and none for HF exacerbation. DISCUSSION: Our case supports the combination of CardioMEMS and levosimendan for the optimal management of patients with advanced HF. These results further strengthen the development of a randomized clinical trial to demonstrate the clinical usefulness of this device in combination with the levosimendan infusion programme in advanced HF patients.
BACKGROUND: In the past years, different devices have been investigated to help in identifying early decompensation events in patients with heart failure (HF) and reduced ejection fraction (EF), reducing hospital admissions. In this report, we present the first patient experience with levosimendan infusion led by CardioMEMS. CASE SUMMARY: A 68-year-old man with HF and reduced EF with more than 20 hospitalizations for exacerbation of HF was enrolled in our HF Clinic from October 2017. Echocardiogram showed a dilated left ventricle with severely reduced EF (29%) and increased pulmonary artery systolic pressure (40 mmHg). From October 2017 to May 2019, the patient went through numerous hospitalizations, despite optimal medical therapy; subsequently, was adopted a strategy of levosimendan infusions guided by CardioMEMS. Levosimendan infusions improved haemodynamic and pressure profiles. The patient was monitored daily by CardioMEMS, and from June to December 2019, he had only two hospitalizations scheduled for levosimendan infusion and none for HF exacerbation. DISCUSSION: Our case supports the combination of CardioMEMS and levosimendan for the optimal management of patients with advanced HF. These results further strengthen the development of a randomized clinical trial to demonstrate the clinical usefulness of this device in combination with the levosimendan infusion programme in advanced HF patients.
Authors: Josep Comín-Colet; Nicolás Manito; Javier Segovia-Cubero; Juan Delgado; José Manuel García Pinilla; Luis Almenar; María G Crespo-Leiro; Alessandro Sionis; Teresa Blasco; Domingo Pascual-Figal; Francisco Gonzalez-Vilchez; José Luis Lambert-Rodríguez; María Grau; Jordi Bruguera Journal: Eur J Heart Fail Date: 2018-02-06 Impact factor: 15.534
Authors: Akshay S Desai; Arvind Bhimaraj; Rupinder Bharmi; Rita Jermyn; Kunjan Bhatt; David Shavelle; Margaret M Redfield; Robert Hull; Jamie Pelzel; Kevin Davis; Nirav Dalal; Philip B Adamson; J Thomas Heywood Journal: J Am Coll Cardiol Date: 2017-03-19 Impact factor: 24.094
Authors: Michael K Ong; Patrick S Romano; Sarah Edgington; Harriet U Aronow; Andrew D Auerbach; Jeanne T Black; Teresa De Marco; Jose J Escarce; Lorraine S Evangelista; Barbara Hanna; Theodore G Ganiats; Barry H Greenberg; Sheldon Greenfield; Sherrie H Kaplan; Asher Kimchi; Honghu Liu; Dawn Lombardo; Carol M Mangione; Bahman Sadeghi; Banafsheh Sadeghi; Majid Sarrafzadeh; Kathleen Tong; Gregg C Fonarow Journal: JAMA Intern Med Date: 2016-03 Impact factor: 21.873
Authors: John J V McMurray; Milton Packer; Akshay S Desai; Jianjian Gong; Martin P Lefkowitz; Adel R Rizkala; Jean L Rouleau; Victor C Shi; Scott D Solomon; Karl Swedberg; Michael R Zile Journal: N Engl J Med Date: 2014-08-30 Impact factor: 91.245
Authors: Piotr Ponikowski; Adriaan A Voors; Stefan D Anker; Héctor Bueno; John G F Cleland; Andrew J S Coats; Volkmar Falk; José Ramón González-Juanatey; Veli-Pekka Harjola; Ewa A Jankowska; Mariell Jessup; Cecilia Linde; Petros Nihoyannopoulos; John T Parissis; Burkert Pieske; Jillian P Riley; Giuseppe M C Rosano; Luis M Ruilope; Frank Ruschitzka; Frans H Rutten; Peter van der Meer Journal: Eur Heart J Date: 2016-05-20 Impact factor: 29.983
Authors: Daniele Masarone; Andrea Petraio; Antonio Fiorentino; Santo Dellegrottaglie; Fabio Valente; Ernesto Ammendola; Gerardo Nigro; Giuseppe Pacileo Journal: Front Cardiovasc Med Date: 2022-02-16